Glycerol Phenylbutyrate oral

FDA Drug Profile — Glycerol Phenylbutyrate

Glycerol Phenylbutyrate oral is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Glycerol Phenylbutyrate. Available dosage form: liquid.

Drug details

Generic Name
Glycerol Phenylbutyrate oral
Brand Names
Glycerol Phenylbutyrate
Application Number
ANDA205742
Sponsor
Camber Pharmaceuticals, Inc.
NDC Codes
2
Dosage Forms
LIQUID
Routes
ORAL
Active Ingredients
GLYCEROL PHENYLBUTYRATE

Indications and Usage

1 INDICATIONS AND USAGE Glycerol phenylbutyrate oral liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate oral liquid must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). Limitations of Use : • Glycerol phenylbutyrate oral liquid is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels. • The safety and efficacy of glycerol phenylbutyrate oral liquid for the treatment of N -acetylglutamate synthase (NAGS) deficiency has not been established. Glycerol phenylbutyrate is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate oral liquid must be used with dietary protein restriction and, in some cases, dietary supplements. ( 1 ) Limitations of Use: • Glycerol phenylbutyrate oral liquid is not indicated for treatment of acute hyperammonemia in patients with UCDs. ( 1 ) • Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.